Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo


Budget 2021

Associate Partners:

  • SMCSamsungVolvo
Webinar :Join an expert panel for a webinar on Smart investments for a secure retirement January 28, 2021. Register now!

Buy Aurobindo Pharma: target of Rs 1024: Sharekhan

Sharekhan is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1024 in its research report dated December 17, 2020.

December 18, 2020 / 01:46 PM IST
  • bselive
  • nselive
Todays L/H

Sharekhan's research report on Aurobindo Pharma

Aurobindo’s US business to stage a marked improvement led by sturdy pipeline of new products, expected traction in the lucrative injectables space and growth in the recently launched products. Further, Aurobindo is investing ~$180 -200 million (~Rs. 1,350-1,500 crore each) towards capacity expansion in FY2021 and FY2022 and encompassing areas of injectables and oral solids across geographies. Aurobindo’s sales and PAT are expected to clock a CAGR of 10% and 14%, respectively, over FY2020-FY2023.


We retain our Buy recommendation on Aurobindo Pharma Limited (Aurobindo) with an unchanged PT of Rs. 1,024.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Dec 18, 2020 01:46 pm

stay updated

Get Daily News on your Browser